Lines of Therapy: New Drugs May Change MBC Treatment
Which therapy to use for the first, second or third line of treatment for metastatic breast cancer is now under rigorous research as more new therapies are available for treating MBC.
PAST ARTICLES
2020
- Surgery & Radiation (Locoregional Therapy) for MBC: Remaining Questions
- HER2-Low Expressing: A New Subcategory of HER2-Negative Breast Cancer?
- Current and Future Uses of Imaging Tests for People with Stage IV Breast Cancer
- PD-L1 Biomarker for Immunotherapy
- What is ER-Low Breast Cancer?
- HER2 Positive Metastatic Breast Cancer Research Update
- Recent FDA Approvals for Metastatic Breast Cancer
- The Tumor Microenvironment
- What is Your Tumor’s Mutation Burden?
- Triple-Negative Breast Cancer Update
2019
- Tips for Reading Cancer News
- What is a Tumor Agnostic Therapy?
- Treating Brain Metastases
- New FDA Approval: A PI3K Inhibitor
- Best of MBC Research News (2018-2019)
- What is Oligometastatic Breast Cancer?
- Getting to the Target: Antibody Drug Conjugates
- First Immunotherapy Approved for MBC
- Liquid Biopsies: More than a Blood Test?
- Get the Latest News on PARP Inhibitors
- New Research Presented at San Antonio
SEARCH OUR SITE
for past articles or specific information.